![]() |
市場調查報告書
商品編碼
1463557
南美洲和中美洲體外診斷市場預測至 2030 年 - 區域分析 - 按產品和服務、技術、應用和最終用戶South & Central America In-Vitro Diagnostics Market Forecast to 2030 - Regional Analysis - by Product & Services, Technology, Application, and End User |
南美洲和中美洲體外診斷市場預計將從2022年的58.7417億美元CAGR到2030年的84.7811億美元。
IVD 技術與數位健康解決方案的整合推動南美洲和中美洲體外診斷市場
IVD 用於臨床、實驗室和門診環境,其具體目的是幫助檢測疾病,從而幫助選擇適當的治療方案。 IVD 技術與數位健康解決方案的整合正在全球範圍內受到關注。數據分析、人工智慧和遠端監控增強了診斷測試的價值,從而實現更好的患者管理和結果。與數位健康解決方案整合的 IVD 技術可以納入臨床決策支援系統。正如世界衛生組織所認知到的,數位健康解決方案可以幫助檢測疾病。人工智慧健康機器人和其他類似的新興解決方案可能會為患者護理帶來機會,並解決高成本和時間要求等挑戰。在基於基因組測試的診斷中,深度學習可以識別癌細胞,確定其類型,並根據特定樣本的圖像預測腫瘤中可能發生哪些突變。體外診斷中的人工智慧和機器學習 (AI/ML) 正在徹底改變醫療設備的開發。這些現代診斷系統促進基於數位影像分析的診斷,從而改善醫療決策。智慧診斷是一種可擴展性極強的 IVD 解決方案,它使用人工智慧,其性能優於基於實驗室的診斷,而價格僅為實驗室診斷的一小部分。此外,這種類型的診斷可以透過獨特的化學和生物特徵檢測和分析來得出新興特徵。因此,IVD 與數位健康技術的整合可能會在未來幾年為體外診斷市場提供利潤豐厚的機會。
南美洲和中美洲體外診斷市場概述
南美洲和中美洲體外診斷市場已細分為巴西、阿根廷以及南美洲和中美洲其他地區。由於慢性病患病率較高、診斷設施數量不斷增加以及醫療保健基礎設施不斷發展,預計該地區的體外診斷市場將在預測期內成長。上述因素對南美洲和中美洲地區體外診斷市場的成長有重要影響。巴西是南美洲和中美洲最大的市場。支持性政府、利潤豐厚的醫療保健政策、發展中的經濟和先進的醫療保健基礎設施等因素為採用現代診斷技術創造了空間。此外,慢性病和傳染病的日益普及預計將推動該國體外診斷市場的成長。根據國際糖尿病聯合會發布的一項研究,該國的糖尿病人口預計將從 2021 年的 1570 萬增至 2045 年的 2180 萬。體外診斷市場的許多主要參與者採取策略性舉措,透過巴西的地理擴張來鞏固其市場。例如,2022 年 8 月,費森尤斯·卡比 (Fresenius Kabi) 與 Bio-Manguinhos/Fiocruz 和 Bionovis 合作,在巴西提供阿達木單抗生物相似藥。此次合作將擴大巴西公共衛生系統 (SUS) 中多種自體免疫疾病的治療選擇。
此外,巴西的老年人口正在高速成長。例如,根據泛美衛生組織統計,巴西60歲及以上人口超過3,000萬,佔該國人口的13%。在開發和隨後實施個人化醫療中使用分子診斷技術可能會促進巴西市場的成長。 2020年2月28日,Cepheid和Sherlock Biosciences合作探索開發新的尖端分子診斷測試。此次合作將重點開發腫瘤疾病和傳染病的分子診斷測試。巴西是拉丁美洲最大的醫療保健市場,其 GDP 的 9.1% 用於醫療保健。 2021年,巴西醫療器材進口額成長7.3%,達62億美元。巴西政府是醫療保健產品的主要買家,這些產品供應給公共醫療保健系統。根據國際貿易管理局的數據,2021 年巴西進口了價值 3.17 億美元的 CBDL 體外診斷試劑和設備。
南美洲和中美洲體外診斷市場收入及 2030 年預測(百萬美元)
南美洲和中美洲體外診斷市場細分
南美洲和中美洲體外診斷市場分為產品和服務、技術、應用、最終用戶和國家。
根據產品和服務,南美洲和中美洲體外診斷市場分為試劑和試劑盒、儀器以及軟體和服務。 2022 年,試劑和試劑盒細分市場在南美洲和中美洲體外診斷市場中佔據最大佔有率。
根據技術,南美洲和中美洲體外診斷市場分為免疫測定/免疫化學、臨床化學、分子診斷、微生物學、血糖自我監測、凝血和止血、血液學、尿液分析等。 2022 年,免疫分析/免疫化學領域在南美洲和中美洲體外診斷市場中佔據最大佔有率。
根據應用,南美洲和中美洲體外診斷市場分為傳染病、糖尿病、腫瘤學、心臟病學、自體免疫疾病、腎臟病學等。 2022 年,傳染病領域在南美洲和中美洲體外診斷市場中佔據最大佔有率。
根據最終用戶,南美洲和中美洲體外診斷市場分為醫院、實驗室、家庭護理等。 2022 年,醫院細分市場在南美洲和中美洲體外診斷市場中佔據最大佔有率。
根據國家/地區,南美洲和中美洲體外診斷市場分為巴西、阿根廷以及南美洲和中美洲其他地區。 2022 年,巴西在南美洲和中美洲體外診斷市場佔據主導地位。
Abbott Laboratories、Becton Dickinson and Co、bioMerieux SA、Bio-Rad Laboratories Inc、Danaher Corp、F. Hoffmann-La Roche Ltd、Qiagen NV、Siemens AG、Sysmex Corp 和Thermo Fisher Scientific Inc 是在這些地區營運的一些領先公司。
The South & Central America in-vitro diagnostics market is expected to grow from US$ 5,874.17 million in 2022 to US$ 8,478.11 million by 2030. It is estimated to grow at a CAGR of 4.7% from 2022 to 2030.
Integration of IVD Technologies with Digital Health Solutions Fuels South & Central America In-Vitro Diagnostics Market
IVD is used in clinical, laboratory, and outpatient settings with the aim specifically to help in the detection of diseases and, consequently, aid in the selection of appropriate treatment protocols. The integration of IVD technologies with digital health solutions is gaining traction globally. Data analytics, artificial Intelligence, and remote monitoring enhance the value of diagnostic tests, leading to better patient management and outcomes. IVD technologies integrated with digital health solutions can be incorporated into clinical decision support systems. As recognized by the WHO, digital health solutions could help detect diseases. Artificial intelligence health bots and similar other emerging solutions may present opportunities for patient care and address challenges such as high cost and time requirements. In diagnostics based on genomic testing, deep learning can identify cancer cells, determine their type, and predict what mutations may occur in a tumor from images of a specific sample. Artificial intelligence and machine learning (AI/ML) in in-vitro diagnostics are revolutionizing medical device development. These modern diagnostic systems facilitate diagnosis based on digital image analysis, thereby improving healthcare decision-making. Smart diagnostics are extremely scalable IVD solutions that use artificial intelligence to perform better than lab-based diagnostics at a fraction of the price. Additionally, this type of diagnostics can derive emergent features through unique chemical and biological signature detection and analysis. Thus, the integration of IVD with digital health technologies is likely to offer lucrative opportunities to the in-vitro diagnostics market in the coming years.
South & Central America In-Vitro Diagnostics Market Overview
The South & Central America in-vitro diagnostics market has been segmented into Brazil, Argentina, and the Rest of South & Central America. The market for in-vitro diagnostics in the region is expected to grow during the forecast period owing to the higher prevalence of chronic conditions, increasing number of diagnostic facilities, and developing healthcare infrastructure. The aforementioned factors are responsible for influential growth of in-vitro diagnostics market in the South & Central America region. Brazil is the largest market in South & Central America. Factors such as supportive government, lucrative healthcare policies, a developing economy, and advancing healthcare infrastructure create scope for adopting modern technologies in diagnostics. Additionally, the increasing prevalence of chronic conditions and infectious diseases is projected to drive the growth of the in-vitro diagnostics market in the country. According to a study published by the International Diabetes Federation, the diabetic population of the country is projected to reach 21.8 million by 2045 from 15.7 million in 2021. Also, according to the estimates, Brazil has the fifth largest diabetic population in the world. A number of major players in the in-vitro diagnostics market take strategic initiatives to consolidate their market through geographic expansions in Brazil. For instance, in August 2022, Fresenius Kabi partnered with Bio-Manguinhos/Fiocruz and Bionovis to provide access to adalimumab biosimilar in Brazil. This partnership will expand treatment options for several autoimmune diseases in the Brazilian Public Health System (SUS).
Additionally, Brazil is witnessing a high rate of growth in the geriatric population. For instance, according to the Pan American Health Organization, Brazil has more than 30 million people aged 60 years or more, which represents 13% of the country's population. The use of molecular diagnostic techniques in developing and, subsequently, administering personalized medicine is likely to boost the market growth in Brazil. On February 28, 2020, Cepheid and Sherlock Biosciences collaborated to explore the development of new cutting-edge molecular diagnostic tests. The collaboration will focus on the development of molecular diagnostic tests for oncological conditions and infectious diseases. Brazil is the largest healthcare market in Latin America, spending 9.1% of its GDP on healthcare. In 2021, Brazil added the imports of medical devices by 7.3%, reaching US$ 6.2 billion. The Government of Brazil is a key buyer of healthcare products, which supply them to the public healthcare system. As per the International Trade Administration ~US$ 317 million CBDL in vitro diagnostic reagents and equipment were imported into Brazil in 2021. Thus, the developing economy and growing diabetes prevalence fuels the in-vitro diagnostics market growth in Brazil.
South & Central America In-Vitro Diagnostics Market Revenue and Forecast to 2030 (US$ Million)
South & Central America In-Vitro Diagnostics Market Segmentation
The South & Central America in-vitro diagnostics market is segmented into product & services, technology, application, end user, and country.
Based on product & services, the South & Central America in-vitro diagnostics market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment held the largest share of the South & Central America in-vitro diagnostics market in 2022.
Based on technology, the South & Central America in-vitro diagnostics market is segmented into immunoassay/ immunochemistry, clinical chemistry, molecular diagnostics, microbiology, blood glucose self-monitoring, coagulation & hemostasis, hematology, urinalysis, and others. The immunoassay/ immunochemistry segment held the largest share of the South & Central America in-vitro diagnostics market in 2022.
Based on application, the South & Central America in-vitro diagnostics market is segmented into infectious diseases, diabetes, oncology, cardiology, autoimmune diseases, nephrology, and others. The infectious diseases segment held the largest share of the South & Central America in-vitro diagnostics market in 2022.
Based on end user, the South & Central America in-vitro diagnostics market is segmented into hospitals, laboratories, homecare, and others. The hospitals segment held the largest share of the South & Central America in-vitro diagnostics market in 2022.
Based on country, the South & Central America in-vitro diagnostics market is segmented int o Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America in-vitro diagnostics market in 2022.
Abbott Laboratories, Becton Dickinson and Co, bioMerieux SA, Bio-Rad Laboratories Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, Qiagen NV, Siemens AG, Sysmex Corp, and Thermo Fisher Scientific Inc are some of the leading companies operating in the South & Central America in-vitro diagnostics market.